For example, stigmasterol, a compound present in soy-derived lipid emulsions used for total parenteral nutrition, showed FXR antagonistic activity, probably contributing to the total parenteral nutrition–induced cholestasis by inhibiting its target genes BSEP, FGF19, and OSTα/β.47 The gene discussed is FGF19; the disease is cholestasis.